- Chemed Corporation recently reported fourth-quarter 2025 results showing net income of US$76.75 million and full-year 2025 net income of US$265.24 million, both lower than the prior year, alongside 2026 adjusted earnings guidance of US$23.25–US$24.25 per diluted share.
- Despite ongoing share repurchases totaling US$2.62 billion since 2011, investors focused on pressure in VITAS and Roto-Rooter margins, including Medicare Cap constraints and water-restoration write-offs.
- We’ll now examine how Chemed’s weaker 2025 earnings and below-consensus 2026 guidance affect its previously optimistic, margin-focused investment narrative.
Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.
Chemed Investment Narrative Recap
To own Chemed, you have to be comfortable with a story built on two cash generative but currently pressured businesses: VITAS hospice and Roto Rooter. Right now, the key near term catalyst is whether 2026 earnings can stabilize after a tough 2025, while the biggest risk is further Medicare and margin pressure at VITAS and weaker profitability at Roto Rooter. The latest earnings miss and below consensus guidance directly challenge that near term margin recovery narrative.
Among recent announcements, the most relevant is Chemed’s 2026 adjusted EPS guidance of US$23.25 to US$24.25 per diluted share. This range came in below analyst expectations and helped trigger the sharp share price reaction, because it reframes how quickly VITAS can offset Medicare Cap effects and how fast Roto Rooter margins can recover, both of which are central to the short term earnings and margin catalyst for the stock.
Yet investors should be aware that the real swing factor may be how Medicare Cap exposure and VITAS’s admission mix evolve from here...
Read the full narrative on Chemed (it's free!)
Chemed's narrative projects $2.9 billion revenue and $351.5 million earnings by 2028. This requires 5.1% yearly revenue growth and about a $61 million earnings increase from $290.3 million today.
Uncover how Chemed's forecasts yield a $555.50 fair value, a 35% upside to its current price.
Exploring Other Perspectives
Before this earnings miss, the most optimistic analysts were modeling revenue of about US$3.0 billion and earnings near US$397 million by 2029, assuming a smoother Medicare Cap backdrop and stronger margins than the base case. That is a much more upbeat path than the consensus view and, in light of the latest guidance and VITAS admission mix issues, it is exactly the kind of assumption you should revisit as you weigh very different opinions on where Chemed can go from here.
Explore 4 other fair value estimates on Chemed - why the stock might be worth as much as 71% more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Chemed research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Chemed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Chemed's overall financial health at a glance.
Looking For Alternative Opportunities?
Our top stock finds are flying under the radar-for now. Get in early:
- Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
- Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
- We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com